Scarica l'app Stockscreener
4.15
5.90%
-0.26
Dopo l'orario di chiusura:
4.15
Precedente Chiudi:
$4.41
Aprire:
$4.42
Volume 24 ore:
49,999
Relative Volume:
0.57
Capitalizzazione di mercato:
$107.36M
Reddito:
-
Utile/perdita netta:
$-35.46M
Rapporto P/E:
-9.8388
EPS:
-0.4218
Flusso di cassa netto:
$-34.00M
1 W Prestazione:
+16.25%
1M Prestazione:
+4.53%
6M Prestazione:
-70.88%
1 anno Prestazione:
-74.21%
Intervallo 1D:
$4.11
$4.42
Intervallo di 1 settimana:
$3.425
$4.76
Portata 52W:
$3.35
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Nome
Contineum Therapeutics Inc
Settore
Industria
Telefono
(858) 333-5280
Indirizzo
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Confronta CTNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
4.15 | 92.36M | 0 | -35.46M | -34.00M | -0.4218 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-22 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-30 | Iniziato | Stifel | Buy |
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Deutsche Bank AG Purchases New Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Northern Trust Corp Increases Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics ATM - Leerink Partners
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook By Investing.com - Investing.com South Africa
Contineum Therapeutics’ SWOT analysis: pipeline progress buoys stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $20.00 at Morgan Stanley - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Earns Outperform Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference - BioSpace
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum Therapeutics May 2025 slides: Multiple shots on goal with 2H25 catalysts ahead - Investing.com India
Barclays PLC Buys 7,978 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Wells Fargo & Company MN Raises Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (CTNM) Expected to Announce Earnings on Thursday - Defense World
(CTNM) Investment Analysis - news.stocktradersdaily.com
Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Jones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy Recommendation - Nasdaq
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target -March 13, 2025 at 08:48 am EDT - Marketscreener.com
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24% - Yahoo Finance
Contineum Therapeutics Inc Azioni (CTNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):